Search research articles
Contact Us
Filters
Showing results (51-60 of 105) with videos related to
Page
of 11
Sort By:
Gynecologic Oncology
|
September 14, 2023
Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue
Alexi A Wright, Hanneke Poort, Anna Tavormina, et al.
JAMA Oncology
|
October 11, 2019
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Joyce F Liu, Christina Herold, Kathryn P Gray, et al.
Gynecologic Oncology
|
July 2, 2026
Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data
Lauren Roller, Ningxuan Zhou, Isha Atre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 2, 2022
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
Jung-Min Lee, Richard G Moore, Sharad Ghamande, et al.
Gynecologic Oncology
|
June 15, 2020
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer
Kathleen N Moore, Michael J Birrer, Jim Marsters, et al.
Gynecologic Oncology
|
June 8, 2024
Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial
Rachel A Pozzar, Andrea C Enzinger, Catherine Howard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 14, 2020
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
William P Tew, Christina Lacchetti, Annie Ellis, et al.
Gynecologic Oncology
|
February 27, 2021
Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors
Elizabeth Schrier, Niya Xiong, Embree Thompson, et al.
JCO Precision Oncology
|
May 16, 2024
Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial
Joyce F Liu, Stéphanie Gaillard, Andrea E Wahner Hendrickson, et al.
Frontiers in Oncology
|
June 18, 2015
CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
Jung-Min Lee, Jane B Trepel, Peter Choyke, et al.
Page
of 11
Search research articles
Search
Showing results (51-60 of 105) with videos related to
Sort By:
Page
of 11
Gynecologic Oncology
|
September 14, 2023
Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue
Alexi A Wright, Hanneke Poort, Anna Tavormina, et al.
JAMA Oncology
|
October 11, 2019
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Joyce F Liu, Christina Herold, Kathryn P Gray, et al.
Gynecologic Oncology
|
July 2, 2026
Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data
Lauren Roller, Ningxuan Zhou, Isha Atre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 2, 2022
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
Jung-Min Lee, Richard G Moore, Sharad Ghamande, et al.
Gynecologic Oncology
|
June 15, 2020
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer
Kathleen N Moore, Michael J Birrer, Jim Marsters, et al.
Gynecologic Oncology
|
June 8, 2024
Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial
Rachel A Pozzar, Andrea C Enzinger, Catherine Howard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 14, 2020
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
William P Tew, Christina Lacchetti, Annie Ellis, et al.
Gynecologic Oncology
|
February 27, 2021
Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors
Elizabeth Schrier, Niya Xiong, Embree Thompson, et al.
JCO Precision Oncology
|
May 16, 2024
Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial
Joyce F Liu, Stéphanie Gaillard, Andrea E Wahner Hendrickson, et al.
Frontiers in Oncology
|
June 18, 2015
CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
Jung-Min Lee, Jane B Trepel, Peter Choyke, et al.
Page
of 11